Surrozen, Inc./DE
About Surrozen, Inc./DE
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.5M
- Net income
- -$242.0M
- Total assets
- $98.7M
- Market cap
- $249.9M
- Operating margin
- -1210.6%
- Net margin
- -6960.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.5M
- Operating expenses
- $45.6M
- Operating income
- -$42.1M
- Income tax
- $0
- Net income
- -$242.0M
- EPS (basic)
- $-32.37
- EPS (diluted)
- $-32.37
Balance sheet
- Total assets
- $98.7M
- Current assets
- $91.6M
- Total liabilities
- $286.5M
- Current liabilities
- $9.9M
- Shareholders’ equity
- -$187.8M
Cash flow
- Operating cash flow
- -$30.2M
- Investing cash flow
- -$128.0K
- Financing cash flow
- $85.1M
- Net cash flow
- $54.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $249.9M
- EPS (diluted)
- $-32.37
- Shares outstanding
- 12.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 12, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $242.0M in FY2025.
- Trading 39% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Surrozen, Inc./DE.
Write a review
News about Surrozen, Inc./DE
News & sentiment via Polygon.io
